FindMyKOL
Clinical trialNCT06285825RecruitingPhase 2Interventional

A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia

NCT06285825 is a phase 2 interventional trial sponsored by M.D. Anderson Cancer Center. As of 21 Nov 2026, it is recruiting participants. It studies Emapalumab in Cytopenia. The registry lists an enrollment of 32 participants at 1 site in 1 country. The registry lists a start date of 5 Jul 2024 and a primary completion date of 22 Aug 2028.

SponsorM.D. Anderson Cancer CenterEnrollment32Cytopenia
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06285825
FieldValue
Registry IDNCT06285825
StatusRecruiting
PhasePhase 2
Study typeInterventional trial
Lead sponsorM.D. Anderson Cancer Center
Enrollment32
Registered sites1
Countries1
ConditionsCytopenia
DrugsEmapalumab
Start5 Jul 2024
Primary completion22 Aug 2028
Study completion22 Aug 2028
Last update posted7 Aug 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To look at the safety and effectiveness of emapalumab for the treatment of prolonged severe cytopenia in participants with LBCL who receive CART.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Texas, United States1 site, 1 recruiting
  • Md Anderson Cancer Center

    Houston

    Paolo Strati, MD
    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 site, 1 recruitingTX1FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06285825

Each answer restates registry values shown on this page.

What is NCT06285825?

NCT06285825 is a phase 2 interventional trial sponsored by M.D. Anderson Cancer Center. It studies Emapalumab in Cytopenia.

Is NCT06285825 recruiting?

As of 21 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT06285825?

The registry names Paolo Strati, MD (principal investigator, M.D. Anderson Cancer Center) as the overall official.

Where does NCT06285825 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT06285825 study?

The registered drug and biological interventions are Emapalumab.

When is NCT06285825 expected to complete?

The registry lists a primary completion date of 22 Aug 2028 and a study completion date of 22 Aug 2028. The sponsor last updated the record on 7 Aug 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.